CRMD - CorMedix Inc Stock Price, Fair Value and News

5.12USD-0.08 (-1.54%)Delayed

Market Summary

USD5.12-0.08

Delayed

-1.54%

CRMD Stock Price

View Fullscreen

CRMD RSI Chart

CRMD Valuation

Market Cap

281.4M

Price/Earnings (Trailing)

-5.6

Price/Sales (Trailing)

4.5K

EV/EBITDA

-5.94

Price/Free Cashflow

-6.16

CRMD Price/Sales (Trailing)

CRMD Profitability

Operating Margin

100.00%

EBT Margin

-63433.82%

Return on Equity

-86.6%

Return on Assets

-73.85%

Free Cashflow Yield

-16.24%

CRMD Fundamentals

CRMD Revenue

CRMD Earnings

Earnings (TTM)

-50.2M

Earnings Growth (Yr)

-36.9%

Earnings Growth (Qtr)

1.95%

Breaking Down CRMD Revenue

Last 7 days

-1.0%

Last 30 days

-5.9%

Last 90 days

54.7%

Trailing 12 Months

15.3%

How does CRMD drawdown profile look like?

CRMD Financial Health

Current Ratio

6.65

CRMD Investor Care

Shares Dilution (1Y)

23.50%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	27.2K	39.9K	52.7K	65.4K
2021	253.4K	245.2K	190.3K	14.4K
2020	193.6K	174.8K	208.3K	239.2K
2019	570.3K	598.0K	285.0K	283.3K
2018	313.0K	184.4K	495.8K	429.8K
2017	222.2K	341.9K	358.5K	329.3K
2016	220.3K	116.8K	125.3K	224.1K
2015	208.3K	288.6K	272.1K	210.1K
2014	0	0	0	189.3K
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CorMedix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	todisco joseph	bought	50,718	3.74	13,561	chief executive officer
Jan 12, 2024	masson-hurlburt elizabeth	acquired	-	-	50,000	evp, head of clinical ops.
Jan 12, 2024	mistry erin	sold (taxes)	-15,229	3.47	-4,389	chief commercial officer
Jan 12, 2024	todisco joseph	acquired	-	-	133,333	chief executive officer
Jan 12, 2024	mistry erin	acquired	-	-	50,000	chief commercial officer
Jan 12, 2024	todisco joseph	sold (taxes)	-47,820	3.47	-13,781	chief executive officer
Jan 12, 2024	david matthew t	sold (taxes)	-18,099	3.47	-5,216	chief financial officer
Jan 12, 2024	masson-hurlburt elizabeth	sold (taxes)	-15,972	3.47	-4,603	evp, head of clinical ops.
Jan 12, 2024	david matthew t	acquired	-	-	50,000	chief financial officer
Dec 15, 2023	dunton alan w	bought	9,900	3.3	3,000	-

Which funds bought or sold CRMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-10,587	23,430	-%
May 16, 2024	Tidal Investments LLC	new	-	59,805	59,805	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-68.47	-154,141	85,033	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	reduced	-32.6	-31,892	101,039	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-83,637	-	-%
May 15, 2024	Elliott Investment Management L.P.	unchanged	-	744,252	6,574,220	0.04%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-9.71	9,811	548,533	-%
May 15, 2024	CITADEL ADVISORS LLC	added	186	340,455	492,998	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	12.59	37,556	176,864	-%
May 15, 2024	Royal Bank of Canada	reduced	-66.25	-48,000	28,000	-%

Are Funds Buying or Selling CRMD?

Are funds buying CRMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRMD

No. of Funds

Unveiling CorMedix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nomura holdings inc	5.4%	2,946,531	SC 13G/A
Feb 13, 2024	vanguard group inc	5.15%	2,825,335	SC 13G
Jan 29, 2024	blackrock inc.	6.4%	3,507,695	SC 13G
Feb 14, 2023	nomura holdings inc	7.2%	2,952,334	SC 13G/A
Jul 08, 2022	blackrock inc.	1.6%	637,778	SC 13G
Feb 14, 2022	nomura holdings inc	5.3%	2,003,612	SC 13G
Feb 03, 2022	blackrock inc.	6.6%	2,500,721	SC 13G/A
Feb 11, 2021	elliott investment management l.p.	4.99%	7,136,979	SC 13D/A
Jan 29, 2021	blackrock inc.	6.2%	1,995,193	SC 13G/A
Aug 10, 2020	elliott investment management l.p.	5.8%	1,758,374	SC 13D

Recent SEC filings of CorMedix Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	4	Insider Trading
May 09, 2024	S-3	S-3
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to CorMedix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

CorMedix Inc News

Latest updates

CorMedix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-	-	-	-	29,702	6,817	21,253	7,636	22,862	38,088	8,191	88,261	55,714	93,020	16,443	74,054	24,778	59,530	35,266	163,692	26,523	372,514
Cost Of Revenue	-	818,539	-	-	406	1,469	332	1,527	48,007	25,166	14,426	61,339	57,232	79,913	19,184	48,517	46,125	79,026	21,128	226,955	22,114	312,434
Gross Profit	-Infinity%	-818,539	-	-	29,296	5,348	20,921	6,109	8,390	12,922	-6,235	26,922	-1,518	13,107	-2,741	25,537	-21,347	-19,496	14,138	-63,263	4,409	60,080
Operating Expenses	1.4%	15,885,697	15,668,744	11,017,179	8,418,524	6,967,282	8,261,366	7,038,470	7,788,310	8,577,841	5,875,993	7,237,440	6,083,122	6,616,862	8,917,868	5,637,285	5,354,477	5,152,019	5,551,494	4,859,918	-2,133,822	10,301,533
S&GA Expenses	12.5%	15,048,252	13,379,855	7,609,677	5,575,302	4,628,014	5,051,895	4,750,883	4,553,091	3,836,613	3,355,790	4,601,108	3,788,693	3,691,507	3,232,576	3,165,168	2,677,470	2,631,027	2,571,587	1,984,922	2,213,440	2,012,439
R&D Expenses	-63.4%	837,445	2,288,889	3,407,502	2,843,223	2,339,268	3,209,471	2,287,587	3,235,219	4,741,228	2,520,203	2,636,332	2,294,429	2,925,355	5,685,292	2,472,117	2,677,008	2,520,992	2,979,907	2,874,996	-4,347,261	8,289,094
EBITDA Margin	-22.7%	-632	-515	-515	-472	-594	-760	-1,040	-1,961	-141	-111	-105	-111	-	-	-	-	-	-	-	-	-
Interest Expenses	50.0%	9,835	6,556	8,776	8,776	8,776	3,585	5,378	5,378	5,381	-	5,184	5,322	7,800	13,828	6,276	6,276	172,429	306,736	302,048	-	-
Income Taxes	-Infinity%	-1,394,770	-	-	-	-	-585,617	-	-	-	-1,250,186	-	-	-3,138	-5,169,395	6,276	-	-	-5,060,778	-	-	-
Earnings Before Taxes	-Infinity%	-15,860,893	-	-10,567,226	-8,208,951	-6,853,721	-8,190,456	-	-7,790,987	-8,569,366	-5,883,121	-	-6,086,945	-6,600,747	-8,951,819	-	-5,304,185	-5,264,847	-5,756,936	-	5,412,604	-10,236,119
EBT Margin	-22.7%	-634	-517	-517	-474	-596	-762	-1,043	-1,966	-142	-112	-106	-112	-	-	-	-	-	-	-	-	-
Net Income	2.0%	-14,466,123	-14,754,029	-10,567,226	-8,208,951	-6,853,721	-7,604,839	-7,034,194	-7,790,987	-8,569,366	-4,632,935	-7,216,938	-6,086,945	-6,600,747	-3,782,424	-5,557,567	-5,304,185	-5,264,847	-696,158	-5,167,884	2,148,518	-10,236,119
Net Income Margin	-8.4%	-768	-708	-508	-454	-556	-776	-1,032	-1,958	-139	-100	-93.46	-92.08	-	-	-	-	-	-	-	-	-
Free Cashflow	-57.3%	-17,371,600	-11,041,625	-10,408,652	-6,283,594	-6,071,854	-5,471,978	-6,748,666	-6,498,121	-6,281,407	-3,097,132	-6,703,892	-6,010,571	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.1%	68.00	82.00	91.00	57.00	59.00	62.00	62.00	68.00	65.00	69.00	75.00	81.00	84.00	49.00	40.00	24.00	27.00	29.00	34.00	28.00	27.00
Current Assets	-20.2%	63.00	79.00	89.00	55.00	57.00	60.00	60.00	65.00	63.00	66.00	73.00	80.00	83.00	48.00	39.00	24.00	27.00	29.00	34.00	27.00	27.00
Cash Equivalents	-19.0%	35.00	44.00	53.00	20.00	25.00	43.00	43.00	49.00	46.00	54.00	67.00	73.00	76.00	42.00	35.00	17.00	12.00	17.00	20.00	15.00	18.00
Inventory	10.2%	2.00	2.00	-	-	-	-	269*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net PPE	2.1%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-16.0%	10.00	12.00	8.00	8.00	5.00	7.00	6.00	6.00	5.00	6.00	6.00	4.00	4.00	5.00	6.00	6.00	6.00	6.00	5.00	11.00	11.00
Current Liabilities	-16.4%	10.00	11.00	8.00	7.00	5.00	6.00	5.00	5.00	4.00	5.00	5.00	3.00	3.00	4.00	5.00	6.00	6.00	6.00	5.00	4.00	4.00
Shareholder's Equity	-17.3%	58.00	70.00	83.00	49.00	54.00	55.00	56.00	62.00	60.00	63.00	69.00	77.00	80.00	44.00	34.00	0.00	22.00	24.00	29.00	16.00	17.00
Retained Earnings	-4.5%	-336	-321	-306	-297	-285	-275	-267	-260	-252	-245	-237	-229	-224	-217	-211	-204	-200	-195	-190	-184	-184
Additional Paid-In Capital	0.6%	394	392	390	346	340	330	323	322	312	308	307	306	305	262	246	223	222	219	219	201	201
Shares Outstanding	0.0%	55.00	55.00	55.00	46.00	44.00	43.00	41.00	40.00	38.00	38.00	38.00	37.00	36.00	34.00	-	-	-	-	-	-	-
Float	-	-	-	-	180	-	-	-	164	-	-	-	208	-	-	-	208	-	-	-	209	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-61.1%	-17,310	-10,745	-8,697	-8,572	-10,393	-6,154	-5,995	-5,462	-6,744	-5,869	-5,503	-3,091	-6,690	-5,933	-7,312	-754	-7,966	-3,884	-3,964	164	-7,367
Share Based Compensation	100.8%	2,444	1,217	1,003	1,057	2,216	874	984	1,074	1,138	1,253	1,048	1,010	1,732	516	611	696	677	453	571	606	809
Cashflow From Investing	1396.3%	8,945	598	-586	-2,385	-14,686	-1.86	-114	594	-4,187	-7,129	-1,271	-208	-526	-1,847	3,243	5,045	985	296	-477	-3,874	-7,964
Cashflow From Financing	-120.8%	-97.12	468	42,899	5,350	7,200	6,046	437	8,411	3,004	-	-	177	41,581	15,322	21,943	-	2,835	-205	10,029	14.00	15,968

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRMD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues, net
Cost of sales	(818,539)
Gross loss	(818,539)
Operating Expenses
Research and development	(837,445)	(3,407,502)
Selling, general and administrative	(15,048,252)	(7,609,677)
Total operating expenses	(15,885,697)	(11,017,179)
Loss From Operations	(16,704,236)	(11,017,179)
Other Income (Expense)
Interest income	857,186	446,384
Foreign exchange transaction (loss) gain	(4,008)	12,345
Interest expense	(9,835)	(8,776)
Total other income	843,343	449,953
Net Loss Before Income Taxes	(15,860,893)	(10,567,226)
Tax benefit	1,394,770
Net Loss	(14,466,123)	(10,567,226)
Other Comprehensive (Loss) Income
Unrealized (loss) gain from investment	(10,903)	16,393
Foreign currency translation gain	256	2,096
Total other comprehensive (loss) income	(10,647)	18,489
Other Comprehensive Loss	$ (14,476,770)	$ (10,548,737)
Net Loss Per Common Share - Basic (in Dollars per share)	$ (0.25)	$ (0.24)
Weighted Average Common Shares Outstanding - Basic (in Shares)	57,503,154	44,090,998

CRMD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 35,180,529	$ 43,642,684
Restricted cash	75,540	77,453
Short-term investments	23,370,989	32,388,130
Inventories	2,320,396	2,106,345
Prepaid research and development expenses	295,845	353,574
Other prepaid expenses and current assets	2,166,267	882,214
Total current assets	63,409,566	79,450,400
Property and equipment, net	1,905,704	1,866,224
License intangible asset	2,000,000
Restricted cash, long-term	103,838	103,055
Operating lease right-of-use asset	604,634	640,278
TOTAL ASSETS	68,023,742	82,059,957
Current liabilities
Accounts payable	2,826,322	4,279,679
Accrued expenses	6,553,311	6,970,217
Operating lease liability, short-term	154,801	150,619
Total current liabilities	9,534,434	11,400,515
Operating lease liability, net of current portion	476,588	517,013
TOTAL LIABILITIES	10,011,022	11,917,528
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS’ EQUITY
Preferred stock - $0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at March 31, 2024 and December 31, 2023	182	182
Common stock - $0.001 par value: 160,000,000 shares authorized; 54,959,270 and 54,938,258 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	54,959	54,938
Accumulated other comprehensive gain	83,461	94,108
Additional paid-in capital	394,040,254	391,693,214
Accumulated deficit	(336,166,136)	(321,700,013)
TOTAL STOCKHOLDERS’ EQUITY	58,012,720	70,142,429
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 68,023,742	$ 82,059,957

About CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CEO	Mr. Joseph Todisco MBA
WEBSITE	cormedix.com
INDUSTRY	Biotechnology
EMPLOYEES	40

CorMedix Inc Frequently Asked Questions

What is the ticker symbol for CorMedix Inc? What does CRMD stand for in stocks?

CRMD is the stock ticker symbol of CorMedix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CorMedix Inc (CRMD)?

As of Fri May 17 2024, market cap of CorMedix Inc is 281.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers. The fair value of CorMedix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CorMedix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CorMedix Inc a good stock to buy?

The fair value guage provides a quick view whether CRMD is over valued or under valued. Whether CorMedix Inc is cheap or expensive depends on the assumptions which impact CorMedix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRMD.

What is CorMedix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CRMD's PE ratio (Price to Earnings) is -5.6 and Price to Sales (PS) ratio is 4.55 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CorMedix Inc's stock?

In the past 10 years, CorMedix Inc has provided -0.034 (multiply by 100 for percentage) rate of return.